SCHEMBL2706154

SCHEMBL2706154

c1ccc2c(c1)ccn2-c1nccs1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 2/20 0.47
CDC7 O00311 1/20 0.47
CDK2 P24941 1/20 0.47
ROCK1 Q13464 1/20 0.47
GLA P06280 1/20 0.47
BIRC5 O15392 1/20 0.42
HSD17B10 Q99714 1/20 0.42
PRKD3 O94806 1/20 0.41
PRKCG P05129 1/20 0.41
PRKCB P05771 1/20 0.41
PRKCA P17252 1/20 0.41
PRKACA P17612 1/20 0.41
PRKACG P22612 1/20 0.41
PRKACB P22694 1/20 0.41
PRKCH P24723 1/20 0.41
PRKCI P41743 1/20 0.41
PRKCE Q02156 1/20 0.41
PRKCQ Q04759 1/20 0.41
PRKCZ Q05513 1/20 0.41
PRKCD Q05655 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28345274 0.78 ROCK1 (0.52) LMNAROCK1GLAHSD17B10CYP17A1
SCHEMBL35210773 0.78 KDM4E (0.51) LMNAGLAHSD17B10MAPTKDM4E
SCHEMBL28256561 0.78 CDC7 (0.52) LMNACDC7CDK2ROCK1GLA
SCHEMBL28258022 0.74 HSD17B10 (0.44) LMNAGLAHSD17B10PDE10ACYP17A1
SCHEMBL28257961 0.74 LMNA (0.43) LMNAGLAHSD17B10CYP17A1CYP1A2
SCHEMBL28257980 0.74 ROCK1 (0.55) ROCK1PDE10AMAPTPTK2
SCHEMBL28256466 0.74 CDC7 (0.55) LMNACDC7CDK2GLAPRKACA
SCHEMBL31525359 0.73 AKR1C3 (0.52) LMNAROCK1GLAALDH1A1MAPK10
SCHEMBL28345895 0.72 ALDH1A1 (0.46) CDC7CDK2ROCK1BIRC5HSD17B10
SCHEMBL1387982 0.72 PDE10A (0.54) LMNAROCK1GLAPDE10ACYP17A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-110862385-B Application of copper catalyst in preparation of thiazoloquinazolinone derivative through reaction of 1-thiazolylindole compound and tert-butyl nitrite 苏州大学 2020-12-08 CN claimed
CN-110862385-A Application of copper catalyst in preparation of thiazoloquinazolinone derivative through reaction of 1-thiazolylindole compound and tert-butyl nitrite 苏州大学 2020-03-06 CN claimed
CN-108774248-B Method for preparing thiazoloquinazolinone derivative 苏州大学 2020-01-14 CN claimed
CN-110862385-B Application of copper catalyst in preparation of thiazoloquinazolinone derivative through reaction of 1-thiazolylindole compound and tert-butyl nitrite 苏州大学 2020-12-08 CN disclosed
CN-110862385-B Application of copper catalyst in preparation of thiazoloquinazolinone derivative through reaction of 1-thiazolylindole compound and tert-butyl nitrite 苏州大学 2020-12-08 CN disclosed
CN-110862385-B Application of copper catalyst in preparation of thiazoloquinazolinone derivative through reaction of 1-thiazolylindole compound and tert-butyl nitrite 苏州大学 2020-12-08 CN disclosed
CN-110862385-A Application of copper catalyst in preparation of thiazoloquinazolinone derivative through reaction of 1-thiazolylindole compound and tert-butyl nitrite 苏州大学 2020-03-06 CN disclosed
CN-110862385-A Application of copper catalyst in preparation of thiazoloquinazolinone derivative through reaction of 1-thiazolylindole compound and tert-butyl nitrite 苏州大学 2020-03-06 CN disclosed
CN-110862385-A Application of copper catalyst in preparation of thiazoloquinazolinone derivative through reaction of 1-thiazolylindole compound and tert-butyl nitrite 苏州大学 2020-03-06 CN disclosed
CN-108774248-B Method for preparing thiazoloquinazolinone derivative 苏州大学 2020-01-14 CN disclosed
CN-108774248-B Method for preparing thiazoloquinazolinone derivative 苏州大学 2020-01-14 CN disclosed
US-7235572-B2 Thiazolyl-indole derivatives, their manufacture and use as pharmaceutical agents HOFFMAN-LA ROCHE INC. (US) 2007-06-26 US disclosed
CN-1312154-C Purine derivatives as kinase inhibitors LILLY CO ELI (US) 2007-04-25 CN disclosed
US-6998492-B2 Organometallic complex and light-emitting element containing the same SEMICONDUCTOR ENERGY LABORATORY CO., LTD. (JP) 2006-02-14 US disclosed
CN-1639165-A Purine derivatives as kinase inhibitors LILLY CO ELI (US) 2005-07-13 CN disclosed
CN-1609101-A Organometallic complex and light-emitting element containing the same SEMICONDUCTOR ENERGY LAB (JP) 2005-04-27 CN disclosed
US-20050033054-A1 Organometallic complex and light-emitting element containing the same SEMICONDUCTOR ENERGY LABORATORY CO., LTD. 2005-02-10 US disclosed
US-20050004187-A1 Thiazolyl-indole derivatives, their manufacture and use as pharmaceutical agents HOFFMANN-LA ROCHE INC. 2005-01-06 US disclosed
US-20050004187-A1 Thiazolyl-indole derivatives, their manufacture and use as pharmaceutical agents HOFFMANN-LA ROCHE INC. 2005-01-06 US disclosed
US-20040230061-A1 Organometallic complex and light-emitting element containing the same SEMICONDUCTOR ENERGY LABORATORY CO., LTD. 2004-11-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050033054-A1 Organometallic complex and light-emitting element containing the same BCKDK, CCNK, CDK20 LMNA 2107/4885CDC7 239/4885CDK2 34/4885
US-20050004187-A1 Thiazolyl-indole derivatives, their manufacture and use as pharmaceutical agents PPARD, PPARA, PPARG LMNA 3202/4885CDC7 4471/4885CDK2 1557/4885
US-20040230061-A1 Organometallic complex and light-emitting element containing the same NR0B1, BCKDK, NR4A1 LMNA 2250/4885CDC7 521/4885CDK2 76/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.